Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics, Inc. reports that CFO and Treasurer Paul Kim had 2,747 shares of common stock withheld on July 26, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units assumed in a 2022 merger. After this tax withholding disposition, he directly owns 359,798 shares.
Fulgent Genetics, Inc. President and COO Jian Xie reported a tax‑withholding disposition of 4,361 shares of common stock on July 26, 2026, at $19.67 per share, to cover taxes from vesting restricted stock units. After this, he directly held 363,244 shares, with an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. (FLGT) reports that Chief Scientific Officer Hanlin Gao had 1,645 shares of Common Stock withheld on July 26, 2026 to satisfy tax withholding obligations from the vesting of restricted stock units assumed in a prior merger, leaving him with 988,729 shares directly held.
Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 2,146 shares of common stock at a weighted-average price of $17.8855 per share on June 2, 2026. According to the disclosure, the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025.
Following the sale, Xie holds 367,605 shares of Fulgent Genetics common stock directly and an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics CFO Paul Kim reported a routine share disposition related to tax withholding. On June 1, 2026, 2,087 shares of common stock were withheld at $18.09 per share to satisfy tax obligations triggered by the vesting of restricted stock units granted on February 25, 2025. After this withholding, Kim directly holds 362,545 shares of Fulgent Genetics common stock, indicating the transaction was a small, non-market event tied to compensation rather than an open-market sale.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of 1,688 shares of common stock at a weighted-average price of $17.8855 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Gao directly holds 990,374 shares of Fulgent Genetics common stock.
Fulgent Genetics CEO Ming Hsieh reported a Form 4 showing shares withheld for taxes on vested stock awards, not an open‑market trade. On June 1, 2026, 4,392 shares of common stock were disposed of at $18.09 per share to satisfy tax withholding obligations from restricted stock units granted on February 25, 2025.
After this tax-withholding disposition, Hsieh directly holds 893,293 common shares. He also has substantial indirect holdings through family and trust structures, including shares held by the Ming Hsieh Trust, the Dynasty Trust, a Uniform Transfers to Minor Act account, and an immediate family member residing in the same household.
Xie Jian, an officer of Fulgent Genetics, Inc. (FLGT), reported a proposed sale of 2,146 common shares, with an aggregate market value of $38,382.27 and an approximate sale date of June 2, 2026. The securities information lists 27,493,435 shares outstanding.
The securities table records an acquisition of 45,304 shares through restricted stock vesting on February 25, 2025, as equity compensation for services rendered. It also lists 1,201 shares sold on May 27, 2026, for gross proceeds of $21,137.57. The remarks state that the proposed sale and sales during the prior three months were to satisfy tax withholding obligations through sell-to-cover transactions, not discretionary trades.
Fulgent Genetics filed an 8-K to share updated clinical data for its cancer drug candidate FID-007. The company presented preliminary Phase 2 results at the ASCO 2026 Annual Meeting in a rapid oral abstract session focused on head and neck cancer.
The open-label, randomized Phase 2 study evaluates two dosing regimens of FID-007 combined with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after PD-1–based immunotherapy. As of the April 16, 2026 data cutoff, investigators reported meaningful clinical activity and a manageable safety profile.
According to a principal investigator, the combination produced an objective response rate of 61.9%, median progression-free survival of 6.7 months, median duration of response of 7.4 months, and one-year overall survival of 63.4%. A Phase 3 study of FID-007 is planned, and the ASCO presentation slides are being made available on Fulgent’s investor relations website.
Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 1,201 shares of common stock on May 27, 2026 at a weighted-average price of $17.60 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024.
Following the sale, Xie directly holds 369,751 shares of Fulgent Genetics common stock. An additional 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.